DNAJA: emerging targets for anti-tumor therapy

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• The DNAJ/HSP40 family is the largest and most diverse HSP70 co-chaperone family, with three subfamilies: DNAJA, DNAJB, and DNAJC.
• The DNAJA subfamily, containing four members, is implicated in various diseases, including cancer, cystic fibrosis, and neurodegenerative disorders.

Purpose of the Study:

• To comprehensively review the role and mechanisms of DNAJA proteins in tumor proliferation and metastasis.
• To investigate the influence of DNAJA proteins on mutant p53 protein accumulation.
• To explore computer-based identified compounds targeting DNAJA for novel cancer combination therapies.

Main Methods:

• Literature review focusing on DNAJA proteins in cancer.
• Analysis of DNAJA's role in mutant p53 accumulation.
• Examination of computational drug discovery approaches targeting DNAJA pathways.

Main Results:

• DNAJA proteins significantly contribute to tumor proliferation and metastasis.
• DNAJA influences the accumulation of mutant p53 proteins, a common event in cancer.
• Computational methods identified potential compounds and pathways for targeting DNAJA.

Conclusions:

• Targeting the DNAJA subfamily presents a promising strategy for anti-tumor therapy.
• Further research into DNAJA's limitations and therapeutic potential is warranted.
• DNAJA is poised to become a significant therapeutic target for cancer interventions.